The global osteoporosis drugs market is projected to generate $22,947.0 million revenue by 2030, advancing at a CAGR of 5.2% during 2021–2030. The key factors driving the market include the increasing healthcare expenditure, surging prevalence of osteoporosis, and rapid urbanization affecting bone health.
Bisphosphonates held the largest market share, around 30%, in 2021. This is mainly because bisphosphonates are the drugs commonly prescribed for the treatment and prevention of osteoporosis. They are enzyme-resistant analogs of pyrophosphate, which inhibits mineralization in the bone. It decreases bone resorption and slows down bone loss, which allows osteoblasts to work efficiently. Further, it helps reduce the risk of fractures and increases bone density in the hip and spine. It also increases bone density by 4–8% in the spine and 1–3% in the hip in 3–4 years of treatment. Moreover, it is administered through injection or orally. Alendronate, risedronate, ibandronate, and zoledronic acid are some of the types of bisphosphonates.
The parathyroid hormone category also held significant market share in 2021. Parathyroid hormone is an 84-amino-acid polypeptide secreted by parathyroid glands. It is also known as a bone formation agent, as it stimulates renal tubular calcium reabsorption and bone resorption. It increases bone density and reduces the risk of spine fracture and other associated osteoporosis. It is administered through injection in the thigh or abdomen. It is used for the treatment of postmenopausal women with severe osteoporosis, increasing bone mass in men with primary or hypogonadal (low testosterone) severe osteoporosis, and the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women.
The APAC market is predicted to grow at the highest CAGR during the forecast period. The growth can be attributed to the growing geriatric population, the increasing healthcare expenditure, and the surging awareness of osteoporotic care in the region. Moreover, key players’ consistent investment in R&D, mergers and acquisitions, and efforts to offer branded and generic medications at competitive prices are projected to contribute to the regional market growth. Also, due to the rising adoption of collaborative methods by important players to preserve a competitive position, the industry is predicted to see fierce rivalry throughout the projected period.
Whereas, North America held the largest revenue share, of over 40%, in 2021, and it is expected to maintain this trend throughout the forecast period. This is primarily attributed to the increase in the awareness about the treatment of osteoporosis, government initiatives in this regard, presence of established players, and rise in the number of product approvals. Moreover, the growing geriatric population, extensive pipeline drugs, and increasing R&D expenditure are supporting to the growth of the osteoporosis drugs market in the continent.
The major players operating in the osteoporosis drugs market include Eli Lilly and Company, Amgen Inc., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.